Quick search:
Content Search
Result Content Research
Result Content Research
1 Praxis Precision Medicines to Present at Citi's 16th Annual
2 Praxis Precision Medicines (PRAX) falls 2.35% for September 17
3 Praxis Precision Medicines (PRAX) falls 2.86% to Close at $19.71 on September 15
4 Praxis Precision Medicines (PRAX) falls 1.19% in Light Trading on September 13
5 Praxis Precision Medicines (PRAX) gains 3.92% in Light Trading on September 10
6 Praxis Precision Medicines (PRAX) gains 9.49% for August 27
7 BofA Initiates Praxis Precision Medical At Buy
8 Praxis Precision Medicines Announces Proposed Public Offering of Common Stock
9 Praxis Precision Medicines Shares Drop 6% After Results for Depression Treatment
10 Praxis Precision Medicines Prices Public Offering of Common Stock
11 Praxis Precision Medicines Adds Development Expertise to Board of Directors with Appointment of Jeffrey Chodakewitz, M.D.
12 Praxis Precision Medicines Inc. (PRAX) Q4 2020 Earnings Call Transcript
13 Praxis Precision Medicines Appoints Tim Kelly as Chief Financial Officer
14 Praxis Precision Medicines Receives Orphan Drug Designation
15 Praxis Precision Medicines Receives Orphan Drug Designation for PRAX-562 for the Treatment of SCN2A-DEE
16 Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
17 Praxis Precision Medicines, Inc. (NASDAQ:PRAX) insiders are still down US$36k after purchasing last year, recent gain helped regain some losses
18 What Kind Of Shareholders Own Praxis Precision Medicines, Inc. (NASDAQ:PRAX)?
19 Praxis Precision Medicines Receives Rare Pediatric Disease
20 Praxis Precision Medicines Announces CFO Transition
21 Praxis Precision Medicines to Present at Upcoming Investor
22 Fresh Off a $110 Million Series C, Praxis Precision Medicines Eyes $190 Million IPO
23 Praxis Precision Medicines Expands Leadership Team to Advance its Pipeline for CNS Disorders
24 Praxis Precision Medicines Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters
25 Praxis Precision Medicines Announces $110 Million Financing
26 Praxis Precision Medicines Launches with over $100 Million to Advance Pipeline of High Impact Therapies for Brain Disorders
27 Praxis Precision Medicines Provides Update On PRAX-114 IND
28 Praxis Precision Medicines, Inc. (PRAX) Stock Price Today, Quote & News
29 Praxis Precision Medicines upsizes IPO by 35%, now looks to raise up to $180 million
30 Praxis Precision Pops 62% as Biotech IPO Party Continues
31 The Four Essential Pillars of Successful Patient Centric Trials
32 The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
33 Aeglea BioTherapeutics Appoints Marcio Souza to Board of Directors
34 Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
35 Praxis Precision Medicines Promotes Business Leader Stuart Chaffee to Chief Financial Officer
36 The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
37 Using AI/ML to reduce the costs and risks of CNS diseases research
38 Scrip Asks…What Does 2021 Hold For Biopharma? Part 4: Technology And Disease :: Scrip
39 Hummingbird Bioscience buzzes with $125M series C led by Novo Holdings
40 How to Optimize Success in Clinical Trials of Antidepressants
41 The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts
42 The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs
43 The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business
44 The Daily Biotech Pulse: Moderna's Vaccine Produces Durable Response Against Variants, FDA Approves Jazz's Sleep Disorder Drug, Dermata IPO
45 Major Depressive Disorder Therapeutic Market Size Expected to Witness Growth at a CAGR of 8.91% for the Study Period 2018-2030 | DelveInsight
46 Scrip Asks…What Does 2021 Hold For Biopharma? Part 5: Business Environment And Strategy :: Scrip
47 The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight
48 Healthcare Stocks Moving Up and Down Tuesday: VRPX, SESN, ARPO, PRAX, MEDXF, QLGN, FLGC, SMFR
49 2021 Major Depressive Disorder Pipeline Insight Report: Insights for Approx 50+ Companies and 50+ Pipeline Drugs
50 The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
51 51 Biggest Movers From Yesterday
52 The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
53 50 Biggest Movers From Friday
54 Invitae, PacBio Collaborate on Epilepsy Diagnostics Development
55 Taking A Life Science Company Public During A Pandemic
56 The Daily Biotech Pulse: Merck Reports Positive Keytruda Data In Breast Cancer, Curis, Evoke Slump On Earnings, Qiagen's Rapid COVID-19 Antibody Test OK'ed For Emergency Use
57 64 Biggest Movers From Yesterday
58 Endowment Sells Off Stocks in Major Technology Companies, Invests in Microsoft and Biopharmaceutical Companies in Fourth Quarter | News
59 Affinivax Appoints Stuart Chaffee, PhD, as Chief Business Officer
60 Behind the Seizure® Program Further Expands Access to Genetic Testing for Children to Speed the Diagnosis of Genetic Epilepsy
61 The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica
62 The Daily Biotech Pulse: Pfizer, BioNTech File Marketing Application In Europe, NuCana Jumps On Data, Amarin Takes On Hikma In Patent Lawsuit
63 Acuta Capital Partners, Llc Buys BCLS Acquisition Corp, Vincerx Pharma Inc, Cyteir Therapeutics Inc, Sells 89bio
64 Benzinga's Top Ratings Upgrades, Downgrades For April 26, 2021
65 The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron
66 The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding
67 PTC Therapeutics Announces Management Change
68 Seeking Alpha Catalyst Watch
69 Q-State Biosciences Announces the Appointment of Biopharma Veteran Paul Medeiros as President and Chief Executive Officer
70 Foghorn Therapeutics Rises 13% in Market Debut
71 Stocks That Hit 52-Week Lows On Tuesday
72 06.25.21 -- Why A CEO Went From Academia To Biopharma
73 Epilepsy Pipeline Review 2020: Therapeutic Analysis Report Featuring 140+ Companies & Drug Profiles
74 Codiak BioSciences Stock Falls in Market Debut
75 IPO, M&A, And SPAC — 3 Life Science Execs Recount Going Public
76 OLB Group slips pre-market on announcing ~$6.1M registered direct offering
77 The Week Ahead In Biotech: Supernus, Sanofi Await FDA Decisions
78 Bio Roundup: SeaGen Scores, Dyne's Debut, Microbiome Moves & More
79 Hearing-Aid Maker Eargo Soars 87% in Its First Trading Day
80 Boeing, Galapagos, Intuitive Surgical: What to Watch When the Stock Market Opens Today
81 Outside GC Expands Life Sciences Team to Meet Growing Industry Demand
82 William Blair Thinks Axsome Therapeutics’ Stock is Going to Recover
83 BUZZ-U.S. STOCKS ON THE MOVE-AnPac Bio, CureVac, Square, PayPal
84 Why Is Coupa Software (COUP) Up 27.6% Since Last Earnings Report?
85 2020 Epilepsy Pipeline Conference
86 WorkBoard's new chat-first experience makes OKR adoption easier than ever
87 AstraZeneca COVID-19 vaccine has 'stronger link’ to blood clots, but benefits outweigh the risk to all ages, Health Canada urges
88 Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
89 Bio Roundup: MESO's Miss, Pfizer's Cancer Bet, Vaccine Promise & More
90 Clean tech is getting a fresh slate in 2020
91 Invitae and Pacific Biosciences Collaborate to Develop Whole Genome Sequencing-Based Assays for Pediatric Epilepsy Diagnostics
92 60 Stock Price Gainers And Losers (March 19, 2021)
93 From race-based to race-conscious medicine: how anti-racist uprisings call us to act
94 Automated and Closed Cell Therapy Processing Systems Markets, 2030
95 Stocks That Hit 52-Week Highs On Friday
96 Our First Look At Relmada Therapeutics
97 ||Gene Therapy Shows Initial Promise for Parkinson's Disease
98 Sage Therapeutics: Showing Upside, But There Are Plenty Of Unknowns
99 Vedanta Biosciences taps Big Pharma vet Jeffrey Silber as CMO; Robert Doebele leaves behind teaching post at Colorado to focus on CSO job at Rain Therapeutics
100 TPG Capital and Vida Ventures fuel RTP's AskBio with $225 million